PAD

authID Selected by National Notarial Centralized Verification System For Secure Biometric Identity Assurance

Retrieved on: 
Thursday, April 18, 2024
PAD, Deepfake, Lawyer, Fraud, Cryptocurrency

Denver, April 18, 2024 (GLOBE NEWSWIRE) -- authID Inc. (Nasdaq: AUID), a leading provider of secure, biometric identity verification and authentication solutions and National Notarial Centralized Verification System (NNCVS), today announced that NNCVS will deploy authID’s biometric identity life-cycle platform to provide real-time identity assurance to the company’s innovative online technology platform for commissioned notaries and their clients. With increasing frequency of social engineering fraud, deepfakes, and ransomware attacks, NNCVS selected authID’s for its ability to stop fraud, detect deepfakes, and combat adversarial generative AI, all while delivering a fast, seamless user authentication experience. 

Key Points: 
  • Denver, April 18, 2024 (GLOBE NEWSWIRE) -- authID Inc. (Nasdaq: AUID), a leading provider of secure, biometric identity verification and authentication solutions and National Notarial Centralized Verification System (NNCVS), today announced that NNCVS will deploy authID’s biometric identity life-cycle platform to provide real-time identity assurance to the company’s innovative online technology platform for commissioned notaries and their clients.
  • Providing the first-ever nationwide verification system for notaries, the NNCVS platform is transforming the current ‘localized and in-person’ notary industry into a robust national online service that makes notarization faster, more efficient, and more secure.
  • “authID’s next-gen biometric identity platform is paramount to our mission to revolutionize the notary industry by providing strong identity assurance that prevents fraudulent account openings and phishing-related account takeovers, while delivering the convenience today’s online users expect,” said Stefan Perez Tejera, CEO of National Notarial Centralized Verification System.
  • “We are excited to help National Notarial Centralized Verification System revolutionize the notary industry by delivering the highest levels of identity trust with market leading speed, precision and accuracy, while deepening user trust with frictionless identity experiences.”

Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks

Retrieved on: 
Monday, March 25, 2024
Failure, HubSpot, Microsoft, Organization, MFA, Risk management, IAD, Science, Partnership, Help desk, PAD, Deepfake, AI, SSPR, Atos, Okta, Machine learning, Fatigue, Zendesk

SEATTLE, March 25, 2024 (GLOBE NEWSWIRE) -- Nametag, the identity verification platform for helpdesks, today announced the launch of Nametag Autopilot, the only self-service account recovery solution that prevents AI-generated deepfake attacks. Account recovery requests represent a significant single point of failure in IT security, susceptible to ransomware, data breaches, and injection attacks, including the use of AI deepfakes. Nametag Autopilot prevents social engineering and impersonation attacks while saving organizations millions by deflecting expensive password and multifactor authentication (MFA) resets to self-service.

Key Points: 
  • HubSpot taps Nametag to secure helpdesk operations, inspire trust, and improve user experience
    SEATTLE, March 25, 2024 (GLOBE NEWSWIRE) -- Nametag , the identity verification platform for helpdesks, today announced the launch of Nametag Autopilot , the only self-service account recovery solution that prevents AI-generated deepfake attacks.
  • So when a helpdesk agent grants an account reset, they inadvertently blow the door wide open to data breaches and ransomware attacks.
  • In this way, Nametag stops account takeovers (ATOs) and data breaches by verifying users at critical moments like account recoveries, MFA resets, and high-risk transactions.
  • “I am excited about our new partnership with Nametag for its account recovery solution as it promises to elevate our customer experience to new heights.

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 22, 2024
Diagnosis, Research, U.S. FDA, Peripheral artery disease, Infection, Patent, Buddha's hand, Evaluation, PAD, Journal, Sale, University, Doctor of Philosophy, Efficacy, Priority review, Regenerative medicine, Clinical trial, Trial of the century, Vascular surgery, HAV, Hospital, Injury, Nationwide Children's Hospital, HUMA, FACS, Amputation, Food, FDA, Defense, BLA, PDUFA, Pharmaceutical industry

DURHAM, N.C., March 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch.

Key Points: 
  • There was no revenue for either the fourth quarter of 2023 or the fourth quarter of 2022, and there was no revenue for the year ended December 31, 2023.
  • Research and development expenses were $20.2 million for the fourth quarter of 2023, compared to $15.0 million for the fourth quarter of 2022, and were $76.6 million for the year ended December 31, 2023, compared to $63.3 million for the year ended December 31, 2022.
  • General and administrative expenses were $6.0 million for the fourth quarter of 2023, compared to $5.8 million for the fourth quarter of 2022, and were $23.5 million for the year ended December 31, 2023, compared to $22.9 million for the year ended December 31, 2022.
  • The 2023 increases in net loss resulted from the non-cash remeasurement of the contingent earnout liability, and operating expense increases, described above.

authID and Verified Inc. Partner to Launch 1-Click Identity Verification

Retrieved on: 
Wednesday, March 13, 2024
Entrepreneurship, Acceleration, Partnership, 1-Click, Level 2, PAD, Insurance, Fraud, PINS, Online shopping

Denver, March 13, 2024 (GLOBE NEWSWIRE) --  authID Inc. (Nasdaq: AUID), a leading provider of secure biometric identity verification and authentication solutions, and Verified Inc., a pioneering digital identity network that powers 1-Click onboarding experiences, today announced a partnership to launch 1-Click identity verification. Through the convergence of authID’s patented biometric identity platform and Verified Inc.’s identity wallet, the companies jointly provide instant, secure, and automated customer onboarding with the highest identity assurance.

Key Points: 
  • Combining best-in-class identity fraud and account takeover prevention with a secure, frictionless customer onboarding experience
    Denver, March 13, 2024 (GLOBE NEWSWIRE) -- authID Inc. (Nasdaq: AUID), a leading provider of secure biometric identity verification and authentication solutions, and Verified Inc. , a pioneering digital identity network that powers 1-Click onboarding experiences, today announced a partnership to launch 1-Click identity verification.
  • Through the convergence of authID’s patented biometric identity platform and Verified Inc.’s identity wallet, the companies jointly provide instant, secure, and automated customer onboarding with the highest identity assurance.
  • The abundance of stolen personal data and the acceleration of AI-driven phishing attacks and account takeovers are driving increasing demand for highly certain identity verification and life-cycle multi-factor authentication.
  • Needing a trusted technology partner to deliver strong identity verification coupled with a seamless user authentication experience, Verified Inc. partnered with authID for its market-leading speed, accuracy and precision.

Johnson & Johnson to Acquire Shockwave Medical

Retrieved on: 
Friday, April 5, 2024
Research, Medical Devices, Health Technology, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Science, Cardiovascular disease, Worldwide, Growth, Peripheral artery disease, Coronary artery disease, Johnson & Johnson, Patient, PAD, JNJ, Perella Weinberg Partners, Acquisition, Electrophysiology, Death, IVL, Medtech, Ventricular fibrillation, European, PCI, Artery, Laminar, Stenosis, Hand, Physician, Percutaneous coronary intervention, CAD, Pharmaceutical industry

Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) and Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave”) today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired.
  • The transaction is expected to accelerate revenue growth for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Delivers immediate operational accretion: The transaction will be accretive to operating margin for both Johnson & Johnson and Johnson & Johnson MedTech.
  • Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Shockwave for $335.00 per share in cash through a merger of Shockwave with a wholly owned Johnson & Johnson subsidiary.

Elixir Medical Receives FDA Breakthrough Device Designation for the DynamX BTK System for Use in the Treatment of Chronic Limb-Threatening Ischemia Resulting From Below-The-Knee Arterial Disease

Retrieved on: 
Thursday, March 21, 2024
Medical Devices, Hospitals, Clinical Trials, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Elixir, Peripheral artery disease, CLTI, Medicine, Risk, Patient, PAD, Mortality, Motion, Life, BTK, Amputation, Marketing, FDA, Circulant matrix, Food, Pharmaceutical industry

The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions.

Key Points: 
  • The DynamX Bioadaptor platform is a medical technology designed to establish the new standard of care for vascular interventions.
  • "The Bioadaptor platform was developed to transform treatment of coronary and peripheral artery disease,” said Motasim Sirhan, CEO at Elixir Medical.
  • “We appreciate the FDA recognition of our innovation for treating the CLTI population with BTK disease and its potential impact on the patients suffering from vascular disease.”
    The FDA Breakthrough Device Designation accelerates the review process for novel technologies designed to address an unmet medical need.
  • Devices that receive breakthrough designation must meet rigorous standards for device safety and effectiveness in order to be authorized for marketing.

Generali Vietnam Life Insurance Company Implements CyberLink FaceMe® Facial Recognition for eKYC Digital Identity Verification

Retrieved on: 
Tuesday, March 19, 2024
Technology, Insurance, Finance, Security, Professional Services, Software, Biometrics, Internet, Health, Artificial Intelligence, Organization, Tablet, PAD, Policy, AI, NIST, CyberLink, ISO, Know your customer, Facial recognition, Risk management

Leading AI facial recognition provider, CyberLink (5203.TW), announced today that it has collaborated with Generali Vietnam Life Insurance Company to integrate facial recognition technology into Generali’s customer application service, GenVita.

Key Points: 
  • Leading AI facial recognition provider, CyberLink (5203.TW), announced today that it has collaborated with Generali Vietnam Life Insurance Company to integrate facial recognition technology into Generali’s customer application service, GenVita.
  • Generali Vietnam is a pioneer in bolstering the mandatory implementation of e-KYC in the life insurance sector to enhance security, transparency, and customer experience.
  • Policy service online transaction: existing policyholders can perform eKYC identity verification to access personal insurance information and conduct transactions.
  • With facial recognition as part of the mandatory eKYC identity verification process, customers' transactions, personal information, and insurance contract content are protected.

Iliac Stent Market Size, Share & Trends Analysis Report 2024: A USD 1.53 Billion Market by 2030, Projected to Grow at a CAGR of 5.8% from 2024 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Surgery, Medical Devices, Hospital, NCBI, Obesity, NMPA, Growth, Prevalence, Peripheral artery disease, Getinge Group, Incidence, Patient, Evaluation, PAD, Plaque, Google Images, National Medical Products Administration, Iliac artery, USD, Marketing, Pharmaceutical industry

The global iliac stent market size is expected to reach USD 1.53 billion by 2030, projected to grow at a CAGR of 5.8% from 2024 to 2030.

Key Points: 
  • The global iliac stent market size is expected to reach USD 1.53 billion by 2030, projected to grow at a CAGR of 5.8% from 2024 to 2030.
  • Furthermore, the growing prevalence of peripheral artery disease (PAD) is expected to propel iliac stents market growth.
  • In 2023, North America held the largest share in the iliac stents market, with a revenue share of 43.7%.
  • Hospitals serve as referral centers where patients receive comprehensive care, including diagnostic imaging, medical management, and interventional procedures like iliac stent placement

Johnson & Johnson to Showcase its Broad Scientific Leadership and Latest Innovations to Combat Cardiovascular Disease at ACC.24

Retrieved on: 
Thursday, April 4, 2024
Cardiology, Abstract, Rivaroxaban, Cardiovascular disease, Worldwide, Peripheral artery disease, Health, Atrial fibrillation, Risk, Patient, Knowledge, PAD, Stroke, Research, Death, Statistics, American College, Danger, Johnson & Johnson, Acute coronary syndrome, Pharmaceutical industry

NEW BRUNSWICK, N.J., April 4, 2024 /PRNewswire/ -- Johnson & Johnson announced today that clinical and real-world evidence from its cardiovascular portfolio will be featured at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) taking place April 6-8, 2024, in Atlanta, Georgia. Eleven abstracts, including five oral presentations, will showcase data from Company-sponsored studies demonstrating therapeutic benefit of breakthrough medicines, such as XARELTO® (rivaroxaban), and interventional technologies, such as those from Abiomed® and Biosense Webster®, to help treat cardiovascular diseases, including atrial fibrillation (AF) and peripheral artery disease (PAD).

Key Points: 
  • "At ACC.24, we look forward to sharing the latest research and innovation from our broad portfolio, including XARELTO®, to equip clinicians and researchers with knowledge and insights that can help transform cardiovascular care for all."
  • Johnson & Johnson is committed to elevating the standard of care in cardiovascular diseases and unlocking the potential of medicines and solutions of tomorrow.
  • Several data presentations at ACC.24 demonstrate how the Company is improving outcomes for people living with cardiovascular disease, including older adults and other patient populations often considered hard to treat.
  • The data we're presenting at ACC.24 demonstrate how we're continuing to deliver on our commitment," said Tim Schmid, Executive Vice President and Worldwide Chairman, Johnson & Johnson MedTech.

FDA Breakthrough Device Designation for BIOTRONIK Freesolve™ Below-the-Knee Resorbable Magnesium Scaffold (RMS)

Retrieved on: 
Thursday, March 21, 2024
CLTI, Coronary artery disease, Patient, PAD, RMS, Mortality, Magnesium, Moyamoya disease, BTK, Safety, Amputation, Physician, Pharmaceutical industry

BUELACH, Switzerland, March 21, 2024 /PRNewswire/ -- BIOTRONIK has been granted Breakthrough Device Designation (BDD) from the US Food and Drug Administration (FDA) for the Freesolve™ below-the-knee resorbable magnesium scaffold (BTK RMS).

Key Points: 
  • The goal of the program is to provide patients and clinicians with timely access to these breakthrough treatments by accelerating their development, assessment and review while maintaining regulatory standards for pre-market approval.
  • "This breakthrough device designation for the Freesolve RMS for BTK treatment is a significant milestone in advancing treatment options.
  • BIOTRONIK is committed to design our products to enhance the lives of patients," stated Ryan Walters, US President at BIOTRONIK.
  • Freesolve, BIOmag and Orsiro are trademarks or registered trademarks of the BIOTRONIK Group of Companies.